Analyze Diet
Microbiology spectrum2017; 5(5); doi: 10.1128/microbiolspec.ARBA-0004-2016

Antimicrobial Resistance in Rhodococcus equi.

Abstract: Pneumonia caused by remains an important cause of disease and death in foals. The combination of a macrolide (erythromycin, azithromycin, or clarithromycin) with rifampin has been the recommended treatment for foals with clinical signs of infection caused by since the early 1980s with, until recently, only rare reports of resistance. Resistance to macrolides and rifampin in isolates of cultured from horses is increasing, with isolates resistant to all macrolides and rifampin now being cultured from up to 40% of infected foals at some farms. This text reviews the available data regarding antimicrobial resistance in , with emphasis on the molecular mechanisms of the recent emergence of resistance to macrolides and rifampin in equine isolates of .
Publication Date: 2017-10-21 PubMed ID: 29052538DOI: 10.1128/microbiolspec.ARBA-0004-2016Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Review
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article examines the increasing resistance to antibiotics in Rhodococcus equi, a bacterium causing pneumonia in foals, with up to 40% of infected foals at some farms hosting bacteria resistant to all recommended treatment options.

Introduction and Research Objective

  • The research paper aims to investigate the rising antimicrobial resistance in Rhodococcus equi. Rhodococcus equi is a bacterium that is primarily known for inducing pneumonia in foals, leading to disease and potentially death.
  • The article intends to provide an analysis of available data regarding antibiotic resistance in this bacterium, with a particular focus on the recent rise in resistance to macrolides and rifampin.

Contextual Background on Pneumonia in Foals

  • Since the 1980s, the combination of a macrolide (such as erythromycin, azithromycin, or clarithromycin) with rifampin has been the recommended treatment for foals showing signs of infection due to Rhodococcus equi.
  • So far, resistance to this treatment has rarely been reported. However, recent observations suggest a disturbing change in this trend.

Emergence of Resistance in Treatment

  • The research article highlights a growing trend of antibiotic resistance among isolates of Rhodococcus equi cultured from horses. The resistance rate is growing to worrying levels, with bacterial samples from up to 40% of infected foals from some farms proving to be resistant to all macrolides and rifampin.
  • The findings are indeed alarming as they mark the increasing impotence of the previously recommended treatment protocol against Rhodococcus equi infection.

Molecular Mechanisms of Emergence of Resistance

  • Furthermore, the paper emphasizes understanding the molecular mechanisms that underlie this newly observed resistance.
  • The research draws attention towards the need for additional study to understand how this resistance has evolved on a molecular level, which could potentially aid in the development of more effective treatments.

Cite This Article

APA
Giguère S, Berghaus LJ, Willingham-Lane JM. (2017). Antimicrobial Resistance in Rhodococcus equi. Microbiol Spectr, 5(5). https://doi.org/10.1128/microbiolspec.ARBA-0004-2016

Publication

ISSN: 2165-0497
NlmUniqueID: 101634614
Country: United States
Language: English
Volume: 5
Issue: 5

Researcher Affiliations

Giguère, Steeve
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA 30605.
Berghaus, Londa J
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA 30605.
Willingham-Lane, Jennifer M
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA 30605.

MeSH Terms

  • Animal Diseases / drug therapy
  • Animal Diseases / microbiology
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azithromycin / pharmacology
  • Clarithromycin / pharmacology
  • Drug Combinations
  • Drug Resistance, Bacterial / genetics
  • Drug Resistance, Bacterial / physiology
  • Erythromycin / pharmacology
  • Fluoroquinolones / pharmacology
  • Horses
  • Lincosamides / therapeutic use
  • Macrolides / pharmacology
  • Microbial Sensitivity Tests
  • Rhodococcus equi / drug effects
  • Rhodococcus equi / isolation & purification
  • Rifampin / pharmacology
  • Streptogramin B / pharmacology

Citations

This article has been cited 21 times.
  1. Knox A, Zerna G, Beddoe T. Current and Future Advances in the Detection and Surveillance of Biosecurity-Relevant Equine Bacterial Diseases Using Loop-Mediated Isothermal Amplification (LAMP). Animals (Basel) 2023 Aug 18;13(16).
    doi: 10.3390/ani13162663pubmed: 37627456google scholar: lookup
  2. Swanner KD, Patel R, Nguyen TT, Patel FN, Magadia R, Rifai AO, Davenport M. A Rare Presentation of Rhodococcus Equi Bacteremia as a Result of Right Upper Arm Cellulitis: A Case Report and Literature Review. Cureus 2023 Apr;15(4):e38295.
    doi: 10.7759/cureus.38295pubmed: 37255906google scholar: lookup
  3. Narváez SÁ, Fernández I, Patel NV, Sánchez S. Novel Quantitative PCR for Rhodococcus equi and Macrolide Resistance Detection in Equine Respiratory Samples. Animals (Basel) 2022 May 3;12(9).
    doi: 10.3390/ani12091172pubmed: 35565598google scholar: lookup
  4. Nielsen SS, Bicout DJ, Calistri P, Canali E, Drewe JA, Garin-Bastuji B, Gonzales Rojas JL, Gortázar C, Herskin M, Michel V, Miranda Chueca MÁ, Padalino B, Pasquali P, Roberts HC, Spoolder H, Ståhl K, Velarde A, Viltrop A, Winckler C, Baldinelli F, Broglia A, Kohnle L, Alvarez J. Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): antimicrobial-resistant Rhodococcus equi in horses. EFSA J 2022 Feb;20(2):e07081.
    doi: 10.2903/j.efsa.2022.7081pubmed: 35136423google scholar: lookup
  5. Nielsen SS, Bicout DJ, Calistri P, Canali E, Drewe JA, Garin-Bastuji B, Gonzales Rojas JL, Gortazar Schmidt C, Herskin M, Michel V, Miranda Chueca MA, Padalino B, Pasquali P, Roberts HC, Sihvonen LH, Spoolder H, Stahl K, Velarde A, Viltrop A, Winckler C, Dewulf J, Guardabassi L, Hilbert F, Mader R, Baldinelli F, Alvarez J. Assessment of animal diseases caused by bacteria resistant to antimicrobials: Horses. EFSA J 2021 Dec;19(12):e07112.
    doi: 10.2903/j.efsa.2021.7112pubmed: 34987627google scholar: lookup
  6. Álvarez-Narváez S, Huber L, Giguère S, Hart KA, Berghaus RD, Sanchez S, Cohen ND. Epidemiology and Molecular Basis of Multidrug Resistance in Rhodococcus equi. Microbiol Mol Biol Rev 2021 May 19;85(2).
    doi: 10.1128/MMBR.00011-21pubmed: 33853933google scholar: lookup
  7. de Lagarde M, Fairbrother JM, Arsenault J. Prevalence, Risk Factors, and Characterization of Multidrug Resistant and ESBL/AmpC Producing Escherichia coli in Healthy Horses in Q, Canada, in 2015-2016. Animals (Basel) 2020 Mar 20;10(3).
    doi: 10.3390/ani10030523pubmed: 32245112google scholar: lookup
  8. Mourenza Á, Collado C, Bravo-Santano N, Gil JA, Mateos LM, Letek M. The extracellular thioredoxin Etrx3 is required for macrophage infection in Rhodococcus equi. Vet Res 2020 Mar 10;51(1):38.
    doi: 10.1186/s13567-020-00763-3pubmed: 32156317google scholar: lookup
  9. Mourenza Á, Gil JA, Mateos LM, Letek M. A Novel Screening Strategy Reveals ROS-Generating Antimicrobials That Act Synergistically against the Intracellular Veterinary Pathogen Rhodococcus equi. Antioxidants (Basel) 2020 Jan 28;9(2).
    doi: 10.3390/antiox9020114pubmed: 32012850google scholar: lookup
  10. Mourenza Á, Bravo-Santano N, Pradal I, Gil JA, Mateos LM, Letek M. Mycoredoxins Are Required for Redox Homeostasis and Intracellular Survival in the Actinobacterial Pathogen Rhodococcus equi. Antioxidants (Basel) 2019 Nov 15;8(11).
    doi: 10.3390/antiox8110558pubmed: 31731720google scholar: lookup
  11. Willingham-Lane JM, Berghaus LJ, Berghaus RD, Hart KA, Giguère S. Effect of Macrolide and Rifampin Resistance on Fitness of Rhodococcus equi during Intramacrophage Replication and In Vivo. Infect Immun 2019 Oct;87(10).
    doi: 10.1128/IAI.00281-19pubmed: 31331959google scholar: lookup
  12. Baptiste KE, Kyvsgaard NC, Ahmed MO, Damborg P, Dowling PM. Is Rifampin (Rifampicin) Essential for the Treatment of Rhodococcus equi Infections in Foals? A Critical Review of the Role of Rifampin. J Vet Pharmacol Ther 2025 Sep;48(5):345-358.
    doi: 10.1111/jvp.70007pubmed: 40552784google scholar: lookup
  13. Huguet AS, Gourbeyre O, Bernand A, Philibert C, Bousquet-Melou A, Lallemand EA, Ferran AA. Comparative bactericidal activity of four macrolides alone and combined with rifampicin or doxycycline against Rhodococcus equi at concentrations achievable in foals. Front Pharmacol 2024;15:1458496.
    doi: 10.3389/fphar.2024.1458496pubmed: 39624843google scholar: lookup
  14. Kabir A, Lamichhane B, Habib T, Adams A, El-Sheikh Ali H, Slovis NM, Troedsson MHT, Helmy YA. Antimicrobial Resistance in Equines: A Growing Threat to Horse Health and Beyond-A Comprehensive Review. Antibiotics (Basel) 2024 Jul 29;13(8).
    doi: 10.3390/antibiotics13080713pubmed: 39200013google scholar: lookup
  15. Hu B, Gao S, Zhang H, Li Q, Li G, Zhang S, Xing Y, Huang Y, Han S, Tian Y, Zhang W, He H. Whole-genome sequencing and pathogenicity analysis of Rhodococcus equi isolated in horses. BMC Vet Res 2024 Aug 12;20(1):362.
    doi: 10.1186/s12917-024-04167-9pubmed: 39129003google scholar: lookup
  16. Liu L, Cai P, Gu W, Duan X, Gao S, Ma X, Ma Y, Ma S, Li G, Wang X, Cai K, Wang Y, Cai T, Zhao H. Evaluation of vaccine candidates against Rhodococcus equi in BALB/c mice infection model: cellular and humoral immune responses. BMC Microbiol 2024 Jul 8;24(1):249.
    doi: 10.1186/s12866-024-03408-zpubmed: 38977999google scholar: lookup
  17. Ranganath N, Mendoza MA, Stevens R, Kind D, Wengenack N, Shah A. Rhodococcus infection: a 10-year retrospective analysis of clinical experience and antimicrobial susceptibility profile. J Clin Microbiol 2024 Mar 13;62(3):e0153723.
    doi: 10.1128/jcm.01537-23pubmed: 38349145google scholar: lookup
  18. Rakowska A, Czopowicz M, Bereznowski A, Witkowski L. Investigation of the relationship between pulmonary lesions based on lung ultrasound and respiratory clinical signs in foals with suspected pulmonary rhodococcosis. Sci Rep 2023 Nov 8;13(1):19401.
    doi: 10.1038/s41598-023-46833-2pubmed: 37938262google scholar: lookup
  19. Kaczmarkowska A, Kwiecień E, Didkowska A, Stefańska I, Rzewuska M, Anusz K. The Genetic Diversity and Antimicrobial Resistance of Pyogenic Pathogens Isolated from Porcine Lymph Nodes. Antibiotics (Basel) 2023 Jun 7;12(6).
    doi: 10.3390/antibiotics12061026pubmed: 37370345google scholar: lookup
  20. Rakowska A, Cywinska A, Witkowski L. Current Trends in Understanding and Managing Equine Rhodococcosis. Animals (Basel) 2020 Oct 18;10(10).
    doi: 10.3390/ani10101910pubmed: 33081047google scholar: lookup
  21. Aslam MW, Lau SF, Chin CSL, Ahmad NI, Rahman NA, Kuppusamy K, Omar S, Radzi R. Clinicopathological and radiographic features in 40 cats diagnosed with pulmonary and cutaneous Rhodococcus equi infection (2012-2018). J Feline Med Surg 2020 Aug;22(8):774-790.
    doi: 10.1177/1098612X19886395pubmed: 32400257google scholar: lookup